Fewer than one in 10 individuals who could benefit from weight-loss injections such as Wegovy can access them, states the global health agency as it publishes its inaugural recommendations on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for more widespread and fairer availability to these injectable treatments.
Based on forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidelines recognises that obesity is a chronic disease that can be treated with thorough and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key hurdles to widespread access to the injections that can assist patients in reducing substantial weight, explains the body.
Skinny Jab Supply Crisis
Even under the current most favorable outlook, the supply of these medications could only cover approximately 100 million people – under 10% of eligible patients, per the health organization.
The guideline encourages countries and companies to expand access, via approaches like licensing agreements.
The intellectual property rights on the active ingredient – the core component of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Jabs Operate
The injections replicate a body's own hormone to reduce digestion speed, curb appetite and boost the sense of being full so people eat less.
Patients commonly begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Research indicates users may put most of the weight back on within a year of stopping the treatment, because their usual hunger come back.
To be above a healthy weight raises your chance for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some cancers.
Excess weight concerns individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
